Brief: Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil
31/03/2025 02:31
March 31 (Reuters) - Mesoblast Ltd MSB.AX: ENTERED INTO MEDICAID NATIONAL DRUG REBATE AGREEMENT WITH U.S. CMS FOR RYONCIL Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil